G
Goldline Pharmaceutical
GLPL BSE
Goldline Pharmaceutical
BSE: GLPL
Key Fundamentals
SMEMarket Cap
₹40.33 Cr
Volatility
Moderate
P/E Ratio
0
EBITDA
₹6.94 Cr
Debt to Equity
1.22
Book Value
₹25.05
52W High
₹60
52W Low
₹33
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Growth Rate
Revenue Growth
11.03% ↘
Net Income Growth
41.43% ↘
Cash Flow Change
-11.64% ↘
ROE
19.21% ↗
ROCE
18.67% ↗
EBITDA Margin (Avg.)
6.97% ↘
Quarterly Results
| Sep 2025 | Mar 2026 | |
|---|---|---|
| Sales | 13.89 | 17.31 |
| Expenses | 11.25 | 13 |
| Operating Profit | 2.64 | 4.31 |
| OPM % | 19.01% | 24.9% |
| Other Income | 0 | 0 |
| Interest | 0.67 | 0.65 |
| Depreciation | 0.12 | 0.12 |
| PBT | 1.85 | 3.54 |
| Tax % | 26.49% | 21.75% |
| Net Profit | 1.36 | 2.76 |
| EPS in Rs | 1.97 | 4 |
Profit & Loss
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales | 19.73 | 23.48 | 28.01 | 31.18 |
| Expenses | 17.32 | 19.14 | 21.86 | 24.09 |
| Operating Profit | 2.41 | 4.34 | 6.15 | 7.09 |
| OPM % | 12.21% | 18.48% | 21.96% | 22.74% |
| Other Income | -0.2 | -0.04 | -0.09 | 0 |
| Interest | 1.63 | 1.61 | 1.95 | 1.46 |
| Depreciation | 0.18 | 0.16 | 0.25 | 0.24 |
| PBT | 0.4 | 2.53 | 3.86 | 5.39 |
| Tax % | 37.5% | 28.46% | 26.42% | 23.38% |
| Net Profit | 0.26 | 1.81 | 2.83 | 4.12 |
| EPS in Rs | 1.3 | 7.87 | 4.1 | 5.97 |
| Div. Payout % | 0% | 0% | 0% | 0% |
Balance Sheet
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 2 | 2.3 | 6.9 | 6.9 |
| Reserves | 2.08 | 3.76 | 1.55 | 5.54 |
| Borrowings | 12.64 | 12.94 | 12.85 | 10.97 |
| Other Liabilities | 2.67 | 3.93 | 4.88 | 5.47 |
| Total Liabilities | 19.39 | 22.93 | 26.18 | 28.88 |
| Fixed Assets | 2.5 | 2.95 | 2.89 | 2.71 |
| CWIP | 0 | 0.45 | 0 | 0 |
| Investments | 0.07 | 0.03 | 0.03 | 0.03 |
| Other Assets | 16.82 | 19.5 | 23.26 | 26.14 |
| Total Assets | 19.39 | 22.93 | 26.18 | 28.88 |
Cash Flow
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Operating | 2.39 | 2.92 | 3.18 | 2.81 |
| Investing | -1.04 | -1.11 | 0.16 | -0.06 |
| Financing | -1.44 | -1.08 | -2.89 | -3.4 |
| Net Cash Flow | -0.09 | 0.74 | 0.45 | -0.65 |
| Free Cash Flow | 1.38 | 1.81 | 3.35 | 2.75 |
| CFO/OP | 101 | 72 | 66 | 53 |
Ratios
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 160 | 150 | 139 | 189 |
| Inventory Days | 336 | 450 | 229 | 202 |
| Days Payable | 54.47 | 98.62 | 69.62 | 60.29 |
| Cash Conversion Cycle | 441 | 501 | 299 | 331 |
| Working Capital Days | 144 | 133 | 134 | 156 |
| ROCE % | — | 23.4% | 29.28% | 30.64% |
Documents
Frequently Asked Questions about Goldline Pharmaceutical
Where is Goldline Pharmaceutical (GLPL) listed?
Goldline Pharmaceutical is listed on the Indian stock exchanges. It is listed on BSE: GLPL. You can view its live share price, financials, and ratios on Tapetide.
What is the market capitalisation of Goldline Pharmaceutical?
Goldline Pharmaceutical has a market capitalisation of approximately ₹40.33 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Goldline Pharmaceutical?
The Price-to-Earnings (PE) ratio of Goldline Pharmaceutical is 0.00. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Goldline Pharmaceutical?
Over the past 52 weeks, Goldline Pharmaceutical has traded between a low of ₹33 and a high of ₹60. This range helps investors understand the stock's price volatility and recent trading levels.
How can I research Goldline Pharmaceutical on Tapetide?
On Tapetide, you can view Goldline Pharmaceutical's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.